|Year : 2016 | Volume
| Issue : 4 | Page : 542-545
Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement
Sanjay Kalra1, Zafar A Latif2, Abdurrahman Comlekci3, Guillermo Gonzalez Galvez4, Rached Malik5, Md Faruque Pathan6, Ajay Kumar7
1 Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India
2 Director, Department of Endocrinology, BIRDEM, Dhaka, Bangladesh
3 Division of Endocrinology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey
4 Department of Endocrinology, Instituto Jalisciense de Investigación en Diabetes y Obesidad, S.C, Mexico
5 Department of Medicine, Setif, Algeria
6 Department of Endocrinology, BIRDEM, Dhaka, Bangladesh
7 Department of Medicine, Diabetes Centre, Patna, Bihar, India
|Date of Web Publication||3-Jun-2016|
Department of Endocrinology, Bharti Hospital, Karnal, Haryana
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Insulin degludec/insulin aspart (IDegAsp) is a modern coformulation of ultra-long-acting basal insulin degludec, with rapid-acting insulin aspart. IDegAsp provides effective, safe, well-tolerated glycemic control, with a low risk of hypoglycemia while allowing flexibility in meal patterns and timing of administration. This consensus statement describes a pragmatic framework to identify patients who may benefit from IDegAsp therapy. It highlights the utility of IDegAsp in type 2 diabetic patients who are insulin-naive, suboptimally controlled on basal or premixed insulin, or dissatisfied with basal–bolus regimens. It also describes potential IDegAsp usage in type 1 diabetic patients.
Keywords: Basal–bolus, basal insulin, coformulation, flexibility, hypoglycemia, insulin, insulin aspart, insulin degludec, insulin degludec/insulin aspart, premixed insulin
|How to cite this article:|
Kalra S, Latif ZA, Comlekci A, Galvez GG, Malik R, Pathan MF, Kumar A. Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement. Indian J Endocr Metab 2016;20:542-5
|How to cite this URL:|
Kalra S, Latif ZA, Comlekci A, Galvez GG, Malik R, Pathan MF, Kumar A. Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement. Indian J Endocr Metab [serial online] 2016 [cited 2021 Apr 13];20:542-5. Available from: https://www.ijem.in/text.asp?2016/20/4/542/182980
| Introduction|| |
Insulin degludec/insulin aspart (IDegAsp) is a modern coformulation of the ultra-long-acting insulin degludec (IDeg) and the rapid-acting analog insulin aspart (IAsp). IDeg and IAsp, are present in a 70:30 ratio to maintain their distinct pharmacokinetic and pharmacodynamic profile in this coformulation. Thus, IDegAsp is able to provide a safe, well-tolerated fasting as well as prandial blood glucose control.
| Clinical Development|| |
IDegAsp is supported by a robust well-designed clinical development program known as BOOST. In phase 3a trials, IDegAsp has been studied in both type 1 and type 2 diabetes. In type 1 diabetes, IDegAsp has been compared, as part of a three-dose regimen (2 doses of IAsp and 1 dose of IDegAsp) with basal–bolus regimens consisting of maximum 4 injections/day. In type 2 diabetes, IDegAsp has been assessed as a once-daily and as a twice-daily dose for both initiation and intensification of therapy.
| Clinical Pharmacology|| |
The pharmacokinetic and pharmacodynamic properties of IDegAsp depend on the action of its two constituents. IDeg is an ultra-long-acting basal insulin with a 25.3 h long half-life, a duration of action of 42 h, and a flat, peakless action-time profile, with low levels of variability. The risk of hypoglycemia and nocturnal hypoglycemia, in particular, is markedly reduced with IDeg as compared with comparator basal insulin. IAsp is a rapid-acting insulin analog, with an onset of action of 10–15 min, peak action at 90 min, and duration of action of 4–5 h. This suggests that IDegAsp can be administered with the main meal of the day to provide both prandial and basal control. There may be occasions when once- or twice-daily administration of IAsp is required for adequate prandial control. This can be safely achieved with two doses of IDegAsp, as IDeg does not lead to stacking due to its first-order elimination kinetics. In case a third injection is necessary for prandial glucose control, a separate dose of IAsp can be added with the third meal.
The duration of the action of IDeg (42 h), its flat action profile, and the lack of stacking allow flexibility in its timing of administration. As IDeg has been studied in forced dosage schedules with interdose gap varying from 8 to 40 h, the same flexibility can be used for IDegAsp as well. In practical terms, this implies that IDegAsp can be administered with the major meal(s) of the day, irrespective of which meal it is, provided that a 6-8 h gap is maintained between injections. This gap is required to ensure that the effect of IAsp component of the first dose is over before the next IDegAsp is injected.
In insulin-naive patients, the starting dose recommended as per label is 10 units/day. In persons on other insulins, a unit-to-unit switch is suggested as per the approved label. However, randomized controlled trials (RCTs) report 10–20% lower dose requirements with IDegAsp as compared to other available premix insulin analogs, biphasic IAsp 30.,
| Patient Profiles|| |
Based on the pharmacological properties of IDegAsp, and clinical experience gained with this molecule in three countries (Mexico, India, and Bangladesh), 10 experts from seven countries discussed and created profiles of patients with type 1 and type 2 diabetes, who would benefit from IDegAsp therapy. This work was done at a full day workshop-based advisory board meeting, held on November 29, 2015, at Vancouver, Canada. It was followed by multiple mails and telephonic discussions before the final draft was agreed upon. The shortlisted patient profiles are listed in [Table 1].
| A) Type 2 Diabetes|| |
- The use of dual action insulin (premixed insulin) as first-line therapy is promoted by guidelines from the International Diabetes Federation and various other countries., IDegAsp can be used as a drug of choice in insulin-naive type 2 diabetes patients
- It provides prandial and basal coverage with one injection and can be administered with the main (largest) meal of the day. Patients retain the flexibility to change the timing of this meal. This convenience is of special importance to persons who have busy or erratic lifestyles and meal patterns, and those who are dependent upon caregivers for injection
- The low risk of hypoglycemia is an advantage for the elderly, the frail, and others at high risk of hypoglycemia, for example, those with renal or hepatic impairment. Directly acting oral insulin secretagogues, such as sulfonylureas and meglitinides, should be discontinued when IDegAsp is initiated.
- IDegAsp can be used to intensify therapy, without increasing the number of injections per day, in persons already on basal insulin or premixed insulin
- Such a switch will be necessary only if there are efficacy issues (poor control), safely/tolerability complaints (unacceptable hypoglycemia or weight gain with effective doses), or dissatisfaction with the rigidity of current insulin preparation (e.g., need to inject at specific times or with specific meals)
- In such cases, basal insulin being prescribed once-daily or twice-daily can be switched to IDegAsp once-daily with the major meal of the day
- While calculating such doses, a unit-to-unit switch should be made for the basal component. Similarly, as per the approved label, patients on conventional or analog premixed insulin should be switched unit-to-unit for the IDegAsp coformulation once-daily or twice-daily, as indicated. If a twice-daily IDegAsp regimen is chosen, a 50:50 distribution of both doses should be begun with, and further titration has to be done as per se lf-monitoring of blood glucose results. It is not necessary to inject two doses of IDegAsp with antipodal meals
- The authors, however, strongly recommend a 10–20% reduction, as compared to the previous premixed dose requirement while calculating starting dose of IDegAsp. This suggestion is supported by data from various BOOST trials, which report a lower dose requirement with IDegAsp than comparator premixed insulin – biphasic IAsp.
- There are patients with type 2 diabetes, who require basal–bolus or basal plus therapy, but are dissatisfied with their treatment. This dissatisfaction may result from excessive variability in glycemic control, unacceptable nocturnal hypoglycemia with “effective” basal doses, and unwillingness to take multiple injectable doses. In such situations, an interchange to IDegAsp-based therapy provides a rational alternative
- Persons on basal plus therapy, taking one basal and one bolus injection, may benefit from the enhanced convenience of a single injection of IDegAsp coformulation
- Those on three injections (one basal and two boluses) may interchange to a twice-daily IDegAsp regimen
- For those on basal–bolus regimes, requiring 4 or 5 injections/day, two options are available. While some persons may be able to achieve adequate glycemic control with twice-daily IDegAsp, other with severe insulin deficiency and/or resistance may require a three-dose intensive regimen. This will consist of IDegAsp with the main meal and IAsp with the other two meals.
In all these scenarios, interchange to IDegAsp or IDegAsp-based regimens allows effective, safe control with lesser number of injections.
| B) Type 1 Diabetes|| |
- IDegAsp can be used as insulin of initiation or as switch (interchange) therapy in type 1 diabetes
- In newly diagnosed, insulin-naive type 1 diabetic patients who are stable and do not require admission for intravenous (IV) insulin, a three-dose, intensive IDegAsp-based regimen can be initiated. This will include one dose of IDegAsp with the major meal and two doses of IAsp with other meals
- In newly diagnosed type 1 diabetic patients who are being discharged from hospital, the first dose of subcutaneous (SC) IAsp should be injected with the first oral meal. Expert recommendations suggest a 15–30 min overlap between the first SC dose of rapid-acting insulin and continuation of IV insulin infusion. Similarly, continuation of IV infusion for 2 h after SC injection of basal insulin is suggested. A pragmatic suggestion would be to inject IDegAsp, in hospital, with the first meal tray and continue a very low-dose IV infusion for 1–2 h after that
- IDegAsp-based intensive therapy can be also used in type 1 diabetic patients already on basal–bolus therapy. Such an interchange or switch will be indicated only if there are efficacy issues (poor fasting control in spite of using intermediate or long-acting insulins such as Neutral Protamine Hagedorn (NPH), glargine, or detemir), safety concerns (unacceptable risk of hypoglycemia with “effective” doses), or inconvenience/dissatisfaction (need for 4–5 doses, with high index of intrusion). In such cases, a three-dose IDegAsp-based intensive regime provides effective, safe, well-tolerated, and a more convenient glycemic control.
| Summary|| |
This consensus statement is based on experience and backed by evidence from RCTs and pharmacokinetic/pharmacodynamic data. It provides a pragmatic framework for diabetes care professionals to help identify patients with type 1 and type 2 diabetes who may benefit from the unique properties of IDegAsp. Wider use of this molecule will help understand the utility of this modern coformulation in the management of diabetes in a better and more suitable manner.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Kalra S. Insulin degludec aspart: The first co-formulation of insulin analogues. Diabetes Ther 2014;5:65-72.
Kalra S, Unnikrishnan AG, Baruah M, Kalra B. Degludec insulin: A novel basal insulin. Indian J Endocrinol Metab 2011;15 Suppl 1:S12-6.
Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, et al.
Insulin aspart (B28 asp-insulin): A fast-acting analog of human insulin: Absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999;22:1501-6.
Kalra S, Gupta Y. Clinical use of insulin degludec: Practical experience and pragmatic suggestions. N Am J Med Sci 2015;7:81-5.
Niskanen L, Leiter LA, Franek E, Weng J, Damci T, Muñoz-Torres M, et al.
Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: A randomised trial. Eur J Endocrinol 2012;167:287-94.
Fulcher G, Bantwal G, Christiansen JS, Andersen T, Mersebach H, Niskanen LK, et al
. Superior FPG Control and Reduced Hypoglycaemia with IDegAsp vs BIAsp 30 in Adults with Type 2 Diabetes Mellitus Inadequately Controlled on Pre/self-mixed Insulin: A Randomised Phase 3 Trial. Poster Presented at EASD 2013 Barcelona. Poster No. 1044; 2013.
Home P, Haddad J, Latif ZA, Soewondo P, Benabbas Y, Litwak L, et al.
Comparison of national/regional diabetes guidelines for the management of blood glucose control in non-western countries. Diabetes Ther 2013;4:91-102.
|This article has been cited by|
||Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns
| ||Tevfik Demir,Serap Turan,Kursad Unluhizarci,Oya Topaloglu,Tufan Tukek,Dilek Gogas Yavuz |
| ||Frontiers in Endocrinology. 2021; 12 |
|[Pubmed] | [DOI]|
||The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia
| ||Sarah J. Glastras,Neale Cohen,Thomas Dover,Gary Kilov,Richard J. MacIsaac,Margaret McGill,Greg R. Fulcher |
| ||Journal of Clinical Medicine. 2020; 9(4): 1091 |
|[Pubmed] | [DOI]|
||Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines
| ||Roopa Mehta,Roger Chen,Takahisa Hirose,Mathew John,Adri Kok,Roger Lehmann,Ambika Gopalakrishnan Unnikrishnan,Dilek Gogas Yavuz,Gregory Fulcher |
| ||Diabetes, Obesity and Metabolism. 2020; |
|[Pubmed] | [DOI]|
||Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp)
| ||Sanjay Kalra,Stephen Atkin,Antonio Cervera,Ashok Kumar Das,Orgur Demir,Tevfik Demir,Md. Fariduddin,Khoa Tuan Vo,Bon Jeong Ku,Ajay Kumar,Zafar A. Latif,Rachid Malek,Bien J. Matawaran,Roopa Mehta,Nam Quang Tran,Araceli Panelo,Sundeep Ruder,Joel Rodriquez Saldana,Khalid A. Shaikh,Amit Shakya,Dina Shrestha,A. G. Unnikrishnan |
| ||Advances in Therapy. 2018; |
|[Pubmed] | [DOI]|
||Expert Opinion: Patient Selection for Premixed Insulin Formulations in Diabetes Care
| ||Sanjay Kalra,Leszek Czupryniak,Gary Kilov,Roberta Lamptey,Ajay Kumar,A. G. Unnikrishnan,Aissa Boudiba,Mohamed Abid,Zhanay A. Akanov,Ali Latheef,Mustafa Araz,Ralph Audehm,Silver Bahendeka,Naby Balde,Sandeep Chaudhary,Chaicharn Deerochanawong,Olufemi Fasanmade,Hinde Iraqi,Tint Swe Latt,Jean Claude Mbanya,Joel Rodriguez-Saldana,Ko Seung Hyun,Zafar A. Latif,Maxim Lushchyk,Magdy Megallaa,Mohammed Wali Naseri,Nguyen Quang Bay,Kaushik Ramaiya,Hoosen Randeree,Syed Abbas Raza,Khalid Shaikh,Dina Shrestha,Eugene Sobngwi,Noel Somasundaram,Norlela Sukor,Rima Tan |
| ||Diabetes Therapy. 2018; |
|[Pubmed] | [DOI]|
||Comment on “Management of postprandial glucose: Recommended targets and treatment with biphasic insulin”
| ||Sanjay Kalra |
| ||Primary Care Diabetes. 2016; |
|[Pubmed] | [DOI]|